For the Inventor, By the Inventor

Enter assignee name

San Jose, CA, United States of America

Ariosa Diagnostics, Inc.

USPTO Granted Patents = 27

CIPO Patents = 3

EPO Patents = 9

Trademarks = 8

Forward Citations = 145

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

Arnold Oliphant (23 out of 49 patents)

Craig Struble (14 out of 21 patents)

Andrew Sparks (14 out of 21 patents)

4. John Stuelpnagel (13 out of 15 patents)

5. Jacob Zahn (10 out of 12 patents)

6. Ken Song (9 out of 10 patents)

7. Eric Wang (6 out of 15 patents)

8. Eric Wang (4 out of 14 patents)

9. Patrick Bogard (3 out of 4 patents)

10. Stephanie Huang (3 out of 4 patents)

11. Kara Juneau (2 out of 3 patents)

12. Morassa Mohseni (2 out of 2 patents)

13. Kara Jeneau (1 out of 1 patent)

27 patents: Sort by Forward Citations

1. 12195799 - Risk calculation for evaluation of fetal aneuploidy (2025-01-14),

2. 11299772 - Assay systems for genetic analysis (2022-04-12),

3. 11289176 - Determination of copy number variations using binomial probability calculations (2022-03-29),

4. 11270781 - Statistical analysis for non-invasive sex chromosome aneuploidy determination (2022-03-08),

5. 11203786 - Detection of target nucleic acids using hybridization (2021-12-21),

6. 11091807 - Assay systems for genetic analysis (2021-08-17),

7. 11031095 - Assay systems for determination of fetal copy number variation (2021-06-08),

8. 10954566 - Ligation-based detection of genetic variants (2021-03-23),

9. 10907198 - Assay systems for genetic analysis (2021-02-02),

10. 10847250 - Determination of copy number variations using binomial probability calculations (2020-11-24),

11. 10718024 - Risk calculation for evaluation of fetal aneuploidy (2020-07-21),

12. 10718019 - Risk calculation for evaluation of fetal aneuploidy (2020-07-21),

13. 10533223 - Detection of target nucleic acids using hybridization (2020-01-14),

14. 10308981 - Assay systems for determination of source contribution in a sample (2019-06-04),

15. 10289800 - Processes for calculating phased fetal genomic sequences (2019-05-14),

Ariosa Diagnostics, Inc. is a leading molecular diagnostics company specializing in non-invasive prenatal testing (NIPT). Their innovative technologies and tests provide accurate and reliable screening for genetic conditions during pregnancy. With a commitment to advancing clinical care, Ariosa Diagnostics aims to improve patient outcomes and empower healthcare providers with valuable genetic information. Visit their website to learn more about their groundbreaking solutions in prenatal testing.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

27 Patents

#260 in San Jose, CA

#2,850 in California

#12,017 in US

#23,316 in the World

San Jose, CA, United States of America

Ariosa Diagnostics, Inc.

Forward Citations = 145

13 inventors:

Arnold Oliphant (23 out of 49 patents)

Craig Struble (14 out of 21 patents)

Andrew Sparks (14 out of 21 patents)

4. John Stuelpnagel (13 out of 15 patents)

5. Jacob Zahn (10 out of 12 patents)

Please report any incorrect information to support@idiyas.com

Loading…